Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025

Stock Information for Aytu BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aytu BioPharma Inc.

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers
Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease
Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM
Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting
Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.